Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
E-MOSAIC: A multicentre randomised controlled trial of longitudinal electronic monitoring of symptoms and syndromes associated with advanced cancer in patients treated with chemotherapy in palliative intention
May 27, 2007RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer receiving palliative c...
Clinical Studies - May 27, 2007 - Mar 31, 2012
Completed
Project leader: Strasser Florian
Members: Linder Susanne, Blum David, Kehl Jeanine
Multiepitop Imfpung von Grad III/IV Melanompatienten mit dendritischen Zellen: Bedeutung von Peptidaffinität und -dichte für die optimale Generierung von tumorspezifischen zytotoxischen T-Lymphozyten
Jan 1, 2007Die immunologische Forschung der letzten Jahre hat deutlich gemacht, dass Krebszellen Zielstrukturen, sogenannte Antigene, produzieren, die sie für einen Angriff durch spezifische Immunzellen sensibilisieren. Die effektivste Waffe des Immunsystems ge...
Clinical Studies - Jan 1, 2007 - Dec 31, 2009
Completed
Project leader: Ludewig Burkhard, Gillessen Sommer Silke, Cerny Thomas
Members: Maier Reinhard, Templeton Arnoud
The European Palliative Care Research Collaborative. Improved treatment of pain, depression and fatigue through translation research
Nov 1, 2006Summary description of project objectives Objective 1 To identify genes and genetic variation relevant for inter-individual variation in opioid responses and genetic variation that may identify patients at particular risk for developing cachexia Obje...
Clinical Studies - Nov 1, 2006 - Oct 31, 2010
Completed
Project leader: Strasser Florian
Members: Linder Susanne, Omlin Aurelius, Oberholzer Rolf, Blum David
Ibritumomab tiuxetan and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy. A multicenter phase I trial
Oct 25, 2006Identification of the maximum tolerated dose (MTD) of melphalan in combination with ibritumomab tiuxetan in patients ≥ 65 years with relapsed or chemotherapy resistant CD20+ lymphoma. Evaluation of feasibility and safety of ibritumomab tiuxetan...
Clinical Studies - Oct 25, 2006 - Oct 25, 2010
Completed
Project leader: Hitz Felicitas
Members: Demmer-Steingruber Ruth
Selectikine plus and minus low dose cyclophosphamide in patients with advanced B cell Non Hodkin Lymphoma and solid tumours
Jul 29, 2006Phase I Dosiseskalationsstudie bei Patienten mit malignen Erkrankungen
Clinical Studies - Jul 29, 2006 - Jul 29, 2009
Automatically Closed
Project leader: Gillessen Sommer Silke
A Phase 2, randomized, non-comparative, two-arm open label, multiple-center study of CP-751,871 in combination with Docetaxel/Prednisone in chemotherapy-naive (Arm A) and Docetaxel/Prednisone refractory (Arm B) patients with hormone insensitive prostate cancer
Jul 29, 2006Phase II Studie in Patienten mit hormon-refraktärem Prostatakarzinom
Clinical Studies - Jul 29, 2006 - Jul 29, 2009
Completed
Project leader: Gillessen Sommer Silke
A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer
Jun 1, 2005Das antihormonelle medikamentöse Standardmedikament ist Tamoxifen. Exemestane ist ein Medikament das bei fortgeschrittenem Brustkrebsleiden bei postmenopausalen Patientinnen angewendet wird. Die Verabreichung dieses Medikaments nach operiertem Brustk...
Clinical Studies - Jun 1, 2005 - Sep 30, 2015
Completed
Project leader: Ruhstaller Thomas
Members: Baumann Michael
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy. A randomized multicenter phase II trial
May 31, 2005The primary objectives of this trial are to evaluate the short-term outcomes and feasibility of neoadjuvant chemotherapy and extrapleural pneumonectomy in Part 1, and long-term outcomes and feasibility of hemithoracic radiotherapy in patients with R0...
Clinical Studies - May 31, 2005 - Mar 31, 2012
Automatically Closed
Project leader: Früh Martin
Members: Neff Claudia
Trastuzumab monotherapy followed by the combination of trastuzumab and letrozole in post-menopausal women with ER-positive, HER-2 positive advanced breast cancer resistant to a nonsteroidal aromatase inhibitor
Jan 1, 2005The primary objective is to determine the efficacy of combined letrozole (L) and trastuzumab (T) in postmenopausal women with ER-positive, HER-2 positive advanced breast cancer resistant to sequential monotherapy of a nonsteroidal aromatase inhibitor...
Clinical Studies - Jan 1, 2005 - Mar 30, 2011
Automatically Closed
Project leader: Köberle Dieter
Members: Baumann Michael
Qualitätssicherungsprotokoll zur Effektivitätssteigerung in der Primärtherapie des intermediären Morbus Hodgkin (4 x ABVD + IF vs. 2 x BEACOPP eskaliert + 2 x ABVD + IF)
Dec 22, 2004Steigerung der Wirksamkeit der Therapie Primärer Endpunkt: Freedom from Treatment Failure (FFTF) Morbus Hodgkin, Erstdiagnose, therapienaiv, histologisch gesichert Alter: 18-60 Jahre Stadium IA, IB, IIA, IIB mit mindestens einem Risikofaktor
Clinical Studies - Dec 22, 2004 - Dec 22, 2012
Automatically Closed
Project leader: Hitz Felicitas
Randomisierter kontrollierter Vergleich von Imatinib vs. Imatinib und Interferon-Alpha vs. Imatinib 800 mg
Sep 27, 2004Qualitätssicherungsprotokoll zur Therapieoptimierung bei chronischer myeloischer Leukämie (CML): Randomisierter kontrollierter Vergleich von Imatinib allein vs. Imatinib und Interferon-Alpha (IFN) vs. Imatinib und niedrigdosiertes AraC vs. Imatinib n...
Clinical Studies - Sep 27, 2004 - Sep 27, 2010
Automatically Closed
Project leader: Hess Urs
A randomized trial of axillary dissection versus no axillary dissection for patients with clinically node negative breast cancer and micrometastases in the sentinel node
Mar 3, 2003Axillary lymph nodes are often metastatic sites of primary breast cancer and are a major prognostic factor. No reliable non-invasive technique is available for detection of lymph node metastases. In most cases, Level I nodes (below pectoralis minor)...
Clinical Studies - Mar 3, 2003 - Feb 28, 2010
Automatically Closed
Members: Kehl Jeanine
Preoperative chemoradiotherapy vs. chemotherapy alone in non-small cell lung cancer (NSCLC) patients with mediastinal lymph node metastases (stage IIIA, N2): A randomized prospective phase III trial
Aug 17, 2001The main objective of this trial is to compare feasibility and efficacy of sequential neoadjuvant chemoradiotherapy with 44 Gy concomitant boost to neoadjuvant chemotherapy alone. Secondary objectives are to assess the value of PET in predicting path...
Clinical Studies - Aug 17, 2001 - Aug 17, 2011
Automatically Closed
Project leader: Früh Martin
Members: Pfister Bogumila
Maintenance Chemotherapy in Hormone Non-Responsive Breast Cancer
Feb 1, 2001Angiogenesis, the process leading to the formation of new blood vessels, plays a central role in tumor progression of solid neoplasia. The switch from the avascular to the vascular phase is generally accompanied by rapid primary tumor growth and loca...
Clinical Studies - Feb 1, 2001 - Feb 1, 2015
Automatically Closed
Project leader: Ruhstaller Thomas
Members: Baumann Michael, Vogel Esther
Randomized phase III trial of Herceptin™ followed by Taxol plus Herceptin™ versus the combination of Herceptin™ and Taxol as palliative chemotherapy in patients with HER2-overexpressing advanced breast cancer
Nov 1, 1999To compare efficacy, toxicity and quality of life of the sequential administration of Her alone followed, at PD, by the combination with weekly Tax (Arm A) vs. the upfront combination of both drugs (Arm B) in patients with ABC.
Clinical Studies - Nov 1, 1999 - Nov 1, 2015
Automatically Closed
Project leader: Ruhstaller Thomas
Members: Baumann Michael
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
Mar 26, 23Diese Studie soll die Wirksamkeit und Sicherheit von ei-nem experimentellen Medikament MK-7684A (Vibosto-limab zusammen mit Pembrolizumab) im Vergleich zu MK-3475 (Pembrolizumab) allein, bei Patienten mit im Stadium IIB–IV (Hochrisiko-Melanom) unters...
Clinical Studies - Mar 26, 23 - Dec 21, 2030
Ongoing
Project leader: Aeppli Stefanie
Members: Sennhauser Andrina